Abstract | PURPOSE: METHODS: One hundred and seventy subjects were randomized and 164 subjects completed all visits. CAC was performed to determine and confirm subjects' eligibility at visits 1 and 2, respectively. The CAC was repeated at visit 3 (day 0 ± 3), 16 hours after study medication instillation, and at visit 4 (day 14 ± 3), 15 minutes after instillation. Ocular itching and conjunctival redness were evaluated after an allergen challenge, along with several secondary endpoints. RESULTS:
Alcaftadine 0.25% and olopatadine 0.1% treatments exhibited significantly lower mean scores compared with placebo for ocular itching and conjunctival redness at visits 3 and 4. Most adverse events were self-limiting and mild in severity. No serious treatment-related adverse events occurred. CONCLUSION: Treatment with alcaftadine 0.25% ophthalmic solution resulted in mean differences of >1 unit (ocular itching) and approximately >1 unit (conjunctival redness), which was significant (P < 0.001) compared with placebo treatment. All doses of alcaftadine were safe and well tolerated in the population studied.
|
Authors | Jack V Greiner, Kimberly Edwards-Swanson, Avner Ingerman |
Journal | Clinical ophthalmology (Auckland, N.Z.)
(Clin Ophthalmol)
Vol. 5
Pg. 87-93
(Jan 13 2011)
ISSN: 1177-5483 [Electronic] New Zealand |
PMID | 21339800
(Publication Type: Journal Article)
|